Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with ...

Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

Cytospire Therapeutics was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of ...

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative ...

Presentation Date / Time : Friday, May 1, 2026 / 2:55 p.m. to 6:00 p.m. EDT ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the ...

WuXi AppTec, a leading global contract research, development, and manufacturing organization (CRDMO) presented 13 scientific posters at the 2026 Annual Meeting of the American Association for Cancer ...

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...

UCB will pay up to $2.2bn for Candid Therapeutics, betting on cizutamig and the wider T-cell engager rush in autoimmune disease.

Researchers from The University of Texas MD Anderson Cancer Center have discovered that some cancer cells express the YAP1 ...